NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

IMAGION BIOSYSTEMS LIMITED (IBX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of IBX: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000IBX6
Address: Level 4 96-100 Albert Road South Melbourne VIC 3205
Tel:  +61 3 9692 7222Fax: +61 2 9956 7355

Date first listed: 22/06/2017

Sector: Pharmaceuticals, Biotechnology & Life Sciences 
Activities: Research and development of medical diagnostics

News & Events

Expand this box to read and print

The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately following lodgement of its Annual Report for the period ending 31 December 2023 and a release of an announcement relating to the appointment of a director.

14/06/2024

The company releases the results of its meeting.

31/05/2024

The company releases its AGM Investor Presentation.

31/05/2024

The company releases its Chairman's Address to Shareholders.

31/05/2024

The company releases its prospectus with a placement of 242,000 Convertible Notes with a face value of $1.00 per Convertible Note and a subscription price of $0.90909 to raise a maximum of approximately $220,000 before costs and grant of 2,048,122 Options.

21/05/2024

The company will be re-instated to official quotation once a new Australian Director is appointed, following the release of its 2023 Annual Report. The ASX will re-instate IBX once it meets s201A(2) of the Corporationorafions Act.

14/05/2024

The company releases its notification of cessation of securities.

10/05/2024

The company releases its Appendix 4G and Corporate Governance Statement.

10/05/2024

The company releases its 2023 Annual Report to shareholders.

10/05/2024

The annual general meeting will be held at Level 25, 525 Collins Street, Melbourne VIC 3000 and virtually via the online platform https://www.web.lumiagm.com/367489986 on Friday 31 May 2024 at 10.00am (AEST).

03/05/2024

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

30/04/2024

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

02/04/2024

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

02/04/2024

The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately, following the release by IBX of an announcement regarding a proposed capital raising.

20/09/2018

The company announces a pro-rata non-renounceable rights issue to shareholders on the basis of 1 new share for every 2 imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018. The funds will finance the company's first in-human study for metastatic breast cancer and for general working capital. The rights issue will be for an issue price of $0.04 per share to raise up to $4.3 million. There will be a shortfall facility to enable applications for additional shares.

20/09/2018

The securities of Imagion Biosystems Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising.

17/09/2018

listed entity carried for record purposes only

22/06/2017

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    27/06/2024Brett Mitchell20,908$0.083$1,744
    19/06/2024Brett Mitchell500,000$0.081$40,499
    12/09/2022Dianne Angus243,000$0.037$8,991
    24/11/2017Robert Proulx235,000$0.100$23,383

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Robert ProulxExecutive Chairman08/12/2016
    David LudvigsonNon Exec Director10/03/2017
    Brett MitchellNon Exec Director14/06/2024
    Mark Gerald Van AstenNon Exec Director08/12/2016
    Michael HarshNon Exec Director02/03/2017
    Melanie LeydinCompany Secretary13/05/2024

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Geoffrey HollisCFO, Company Secretary01/12/202010/05/2024
    Jovanka NaumoskaNon Exec Director08/12/201603/05/2024
    Dianne AngusNon Exec Director08/05/202002/05/2024
    Isaac BrightCEO20/06/202315/01/2024
    Brian ConnCFO22/06/201701/08/2020
    Bronwyn Le GriceNon Exec Director26/04/201831/03/2020
    John HazleNon Exec Director30/07/201827/06/2019
    Peter Di ChiaraNon Exec Director28/04/201726/04/2018

    Date of first appointment, title may have changed.